BioAtla, Inc. Common Stock (BCAB) Stock Price

BCABStock

$1.36−96.31%52W

Market Cap$2.27M

P/E—

PEG Ratio—

Div yield—

Beta0.61

BCAB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-78.06%

Price vs S&P 500 (4W)-27.84%

VGM Score36.52

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)100.00%

Cash Flow / Share (Quarterly)$-14.12

Price vs S&P 500 (YTD)-107.13%

Net Profit Margin (TTM)-109.79%

EPS (TTM)$-25.56

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-25.56

Revenue Growth (5Y)-17.40%

EPS (Annual)$-50.64

ROI (Annual)-489.14%

Net Profit Margin (5Y Avg)-10141.16%

Cash / Share (Quarterly)$0.93

ROA (Last FY)-431.06%

Revenue Growth TTM (YoY)-81.82%

EBITD / Share (TTM)$-23.17

ROE (5Y Avg)-157.04%

Operating Margin (TTM)-110.99%

Cash Flow / Share (Annual)$-37.99

P/B Ratio4.14x

P/B Ratio (Quarterly)37.03x

Net Income / Employee (Annual)$-1,453,800

EV / Revenue (TTM)0.08x

Net Interest Coverage (TTM)-11.49x

ROA (TTM)-263.17%

EPS Incl Extra (Annual)$-50.64

Current Ratio (Annual)0.37x

Quick Ratio (Quarterly)0.17x

3-Month Avg Trading Volume0.06M

52-Week Price Return-96.31%

Revenue / Employee (TTM)$207,300

Tangible BV / Share (Quarterly)$1.98

P/S Ratio (Annual)1.13x

Asset Turnover (Annual)0.14x

52-Week High$71.50

Operating Margin (5Y Avg)-10037.90%

EPS Excl Extra (Annual)$-50.64

26-Week Price Return-68.15%

Quick Ratio (Annual)0.32x

13-Week Price Return-65.57%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.20x

Enterprise Value$721,900

Revenue / Share Growth (5Y)-26.83%

Asset Turnover (TTM)0.73x

Revenue / Employee (Annual)$48,800

Pretax Margin (Annual)-2980.35%

Cash / Share (Annual)$5.61

3-Month Return Std Dev216.70%

Net Income / Employee (TTM)$-767,200

ROE (Last FY)-489.14%

Net Interest Coverage (Annual)-15.82x

EPS Basic Excl Extra (Annual)$-50.64

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-25.56

ROI (TTM)-357.92%

P/S Ratio (TTM)0.27x

Pretax Margin (5Y Avg)-10141.39%

Revenue / Share (Annual)$1.70

Tangible BV / Share (Annual)$3.79

Price vs S&P 500 (52W)-111.84%

Year-to-Date Return-95.21%

5-Day Price Return8.80%

EPS Normalized (Annual)$-50.64

ROA (5Y Avg)-150.40%

Net Profit Margin (Annual)-2980.35%

Month-to-Date Return4.62%

Cash Flow / Share (TTM)$-2.64

EBITD / Share (Annual)$-50.41

Operating Margin (Annual)-2985.55%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-157.03%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-25.56

P/TBV (Quarterly)0.80x

P/B Ratio (Annual)2.40x

Pretax Margin (TTM)-109.79%

Book Value / Share (Annual)$12.28

Price vs S&P 500 (13W)-68.25%

Beta0.61x

Revenue / Share (TTM)$5.12

ROE (TTM)-357.92%

52-Week Low$1.07

vGradeB

gGradeF

mGradeD

vgmGradeD

BCAB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 13, 2025	-$14.83	-$13.50	+8.99%(+$1.33)
Q2 2025	Aug 7, 2025	-$14.67	-$16.00	-9.09%(-$1.33)
Q1 2025	May 6, 2025	-$14.67	-$13.00	+11.36%(+$1.67)
Q4 2024	Mar 28, 2025	-$19.00	-$15.00	+21.05%(+$4.00)

BCAB Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
BCABBioAtla, Inc. Common Stock	B	F	D	0.3x	-81.8%	—	—	$1.36
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About BioAtla, Inc. Common Stock

BioAtla Inc is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for solid tumor cancers. The company's pipeline includes multiple programs featuring designed antibodies and bispecific antibodies, with lead candidates mecbotamab vedotin, ozuriftamab vedotin, and evalstotug in development, along with a Phase 1 trial for BA3182, a bispecific antibody targeting EpCAM and CD3. Its focus on precision-engineered antibodies aims to address unmet needs in oncology with potentially improved specificity and tolerability compared to conventional approaches.